Avelumab Plus Lorlatinib Active in ALK+ NSCLC

An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was not safe or effective against non –ALK-driven cases.

Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news